PROTAC 工程化蛋白/DNA 纳米抗原是癌症免疫治疗中树突状细胞疫苗的有效增强剂
PROTAC-Engineered Protein/DNA Nanoantigen is a Potent Booster for Dendritic Cell Vaccines in Cancer Immunotherapy.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
HIFU-CCL19/21 轴增强树突状细胞疫苗在肿瘤微环境中的疗效
英文原题：HIFU-CCL19/21 Axis Enhances Dendritic Cell Vaccine Efficacy in the Tumor Microenvironment.
查看英文原题
HIFU-CCL19/21 Axis Enhances Dendritic Cell Vaccine Efficacy in the Tumor Microenvironment.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
研究概要
M-HIFU 通过 CCL19/21 有效促进 DC 疫苗的迁移，为癌症治疗提供了一种有前景的方法。建议进一步研究以优化这一联合方案用于临床应用，有望改善难治性癌症类型的患者预后。
研究思路结论见上方概要
背景
有效靶向治疗抵抗性肿瘤细胞，特别是参与肿瘤复发的癌症干细胞（CSCs），仍是免疫治疗中的一大挑战。本研究探讨将机械性高强度聚焦超声（M-HIFU）与树突状细胞（DC）疫苗联合使用，以增强针对表达OLFM4肿瘤的免疫应答的潜力，OLFM4是一种与免疫逃逸和肿瘤生长相关的CSC标志物。
方法
M-HIFU通过机械破坏肿瘤细胞、释放肿瘤相关抗原并营造免疫刺激环境，诱导免疫原性细胞死亡。随后，在该预激活环境中给予负载OLFM4的DC疫苗，以增强免疫应答。
结果
M-HIFU与DC疫苗的联合显著抑制了肿瘤生长和转移，T细胞活化增强，免疫细胞募集增加，这是由于趋化因子CCL19和CCL21升高所致。这种协同作用促进了免疫记忆，降低了复发的可能性。
展开英文摘要原文
METHODS
M-HIFU was applied to induce immunogenic cell death by mechanically disrupting tumor cells, releasing tumor-associated antigens and creating an immunostimulatory environment. DC vaccines loaded with OLFM4 were then administered to boost the immune response within this primed environment.
RESULTS
The combination of M-HIFU and DC vaccine significantly inhibited tumor growth and metastasis, with enhanced T-cell activation and increased recruitment of immune cells due to elevated chemokines CCL19 and CCL21. This synergy promoted immune memory, reducing the likelihood of recurrence.
CONCLUSIONS
M-HIFU effectively promotes the migration of DC vaccines through CCL19/21, presenting a promising approach for cancer treatment. Further studies are recommended to optimize this combination for clinical applications, with potential to improve patient outcomes in challenging cancer types.
论文信息
- 作者
- Baek BS、Park H、Choi JW、Lee EY、Seong SY
- 单位
- Wide River Institute of Immunology, Seoul National University College of Medicine, Hongcheon 25159, Gangwon, Republic of Korea.South Korea
- 期刊
- Pharmaceutics2025 Jan 6
- 原文标识
- PubMed 39861713 · DOI 10.3390/pharmaceutics17010065
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →